Loading...
•
Dec 31, 2021
LifeStance Q4 2021 Earnings Report
LifeStance reported a 61% increase in fourth-quarter revenue and a 55% increase in clinician base.
Key Takeaways
LifeStance Health Group, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2021, with a 61% increase in fourth-quarter revenue to $190.1 million and a 55% increase in the clinician base to 4,790 clinicians.
Fourth quarter revenue increased 61% to $190.1 million.
Clinician base increased 55% to 4,790 clinicians, including 415 net clinician adds in the fourth quarter.
Net loss of $108.0 million in the fourth quarter.
Adjusted EBITDA of positive $11.4 million in the fourth quarter.
LifeStance
LifeStance
Forward Guidance
LifeStance is reiterating its preliminary outlook for 2022 revenue growth rate in the low 30s and Adjusted EBITDA dollar growth rate on pace with, or slightly greater than, revenue. The company expects full year revenue of $865 to $885 million, Center Margin of $240 to $255 million, and Adjusted EBITDA of $63 to $67 million.
Positive Outlook
- Ability to execute on profitable growth strategy.
- Expand clinician population.
- Deliver best-in-class outpatient mental health services.
- Unique hybrid model provides competitive advantages.
- Operational flexibility.
Challenges Ahead
- Plan to strategically moderate our de novo center openings in the second half of 2022 to improve profitability.
- Expect to open 80 to 90 de novo centers this year, compared to over 100 last year.
- Can flex the pace of physical location expansion based on current and projected patient and clinician demand for in-person visits.
- Mix of telehealth visits is currently over 80%.
- Omicron is expected to have an estimated revenue impact in the range of $3 to $7 million in the first quarter.